SNOA vs DERM vs SKIN vs PRGO vs AMRX

For growth investors, Sonoma Pharmaceuticals, Inc.

(SNOA) is the stronger pick with 12. 2% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Amneal Pharmaceuticals, Inc. (AMRX) offers the better valuation at 60. 0x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Amneal Pharmaceuticals, Inc.

(AMRX) delivered a total return of +148. 6%, compared to -99. 2% for Sonoma Pharmaceuticals, Inc. (SNOA). Over 10 years, the gap is even starker: DERM returned -46. 6% versus SNOA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sonoma Pharmaceuticals, Inc.

(SNOA) is the lower-risk stock at 0. 84β versus Journey Medical Corporation's 1. 78β — meaning DERM is approximately 111% more volatile than SNOA relative to the S&P 500. On balance sheet safety, Sonoma Pharmaceuticals, Inc. (SNOA) carries a lower debt/equity ratio of 7% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sonoma Pharmaceuticals, Inc.

(SNOA) is pulling ahead at 12. 2% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Amneal Pharmaceuticals, Inc. grew EPS 157. 9% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amneal Pharmaceuticals, Inc.

(AMRX) is the more profitable company, earning 2. 4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -26. 0% for SNOA. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 69. 9x for Journey Medical Corporation — 64. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. SNOA, DERM, SKIN, AMRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

21), 9. 8% yield). Journey Medical Corporation (DERM) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, DERM: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SNOA (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive) and PRGO (Healthcare) and AMRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SNOA is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; AMRX is a small-cap quality compounder stock. PRGO pays a dividend while SNOA, DERM, SKIN, AMRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.